This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Anacor Pharmaceuticals Announces Positive Preliminary Results From AN2728 MUSE Study In Pediatric And Adolescent Patients With Atopic Dermatitis

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced positive results from its maximal use systemic exposure (MUSE) study of its boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728, in pediatric and adolescent patients with atopic dermatitis. The results of this study demonstrate that AN2728 Ointment, 2% appears to be safe, well-tolerated, and efficacious when applied twice daily to patients, ages two to 18 years with atopic dermatitis affecting a very large percentage of their body surface area.

“The results of this study are very encouraging. Atopic dermatitis primarily affects children and has a big impact on the quality of life of patients and their families. Atopic dermatitis is primarily treated with topical agents, and physicians are constantly looking for alternatives to steroids. AN2728 has the potential to become a widely used treatment,” said Adelaide A. Hebert, M.D., Professor and Director of Pediatric Dermatology at the University of Texas Medical School at Houston.

“This was an important study as it represents the first time we have treated patients in the 2 – 11 year age group, an age range that encompasses most atopic dermatitis patients,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals. “We are pleased to see the efficacy and safety profile demonstrated in this study, as it represents the final significant hurdle before holding an End of Phase 2 meeting with the FDA.”

AN2728 MUSE Study

The multi-center, open label study enrolled 34 patients, ages two to 18 years with mild-to-moderate atopic dermatitis with a mean involvement of 48% of total body surface area (BSA). Mild-to-moderate atopic dermatitis was defined as an Investigator Static Global Assessment (ISGA) score of 2 (“mild”) or 3 (“moderate”). The ISGA is a 5-point scale from 0 (“clear”) to 4 (“severe”). Patients (or their caregivers) were instructed to apply AN2728 Ointment, 2% twice daily for 28 days.

Primary endpoints included an assessment of safety and tolerability based on the frequency and severity of systemic and local adverse events (AE’s) as well as the pharmacokinetic profile when AN2728 Ointment, 2% is applied under maximal use conditions to pediatric and adolescent patients with atopic dermatitis. Secondary endpoints included descriptive assessments of improvement in the severity and extent of disease based on the ISGA, signs and symptoms of atopic dermatitis and treatable percent of body surface area.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,630.27 +189.68 1.09%
S&P 500 2,093.25 +25.61 1.24%
NASDAQ 5,089.2060 +49.43 0.98%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs